Browse studies

Find your next paid study

231 recruiting studies matching your filters

Natural History of Noncirrhotic Portal Hypertension

Background: \- Noncirrhotic Portal Hypertension (NCPH) is caused by liver diseases that increase pressure in the blood vessels of the liver. It seems to start…

Cystic FibrosisImmunologic Deficiency SyndromeTurner Syndrome+2 more

Estimated

~$10 – $675

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT02417740

Phase 3

A Phase 3, Double-Blind, Randomized Trial Evaluating the Efficacy and Safety of Elritercept (TAK-226) Compared to Placebo in Participants With Myelofibrosis and Anemia on Concurrent Ruxolitinib Therapy

The main aim of this study is to find out how well elritercept works to improve anemia in participants with myelofibrosis (MF) who are taking ruxolitinib when …

A Multinational, Long-Term, Safety and Tolerability, Open-Label Extension Study of Subjects Who Have Participated in Avalyn Pharma Studies of Inhaled Antifibrotic Agents (AP-LTE-008 [SAIL])

This is an open-label extension study for participants who were previously enrolled in and completed an Avalyn Pharma Sponsored study with an inhaled antifibro…

Progressive Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)

Estimated

~$10 – $8,750

Avalyn Pharma Inc.NCT06951217

Natural History of Bronchiectasis

Background: * Bronchiectasis is a disease characterized by airways that are inflamed, abnormally dilated, and chronically infected. Individuals with bronchiec…

BronchiectasisCystic FibrosisAutoimmune Disease+1 more

Estimated

~$10 – $675

National Heart, Lung, and Blood Institute (NHLBI)NCT00943514

Phase 1

A Phase 1b Study of Safety, Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)

The purpose of this clinical trial is to learn if the study drug ropeginterferon alfa- 2b added to, standard of care, ruxolitinib is safe and effective in trea…

Myelofibrosis

Estimated

~$10 – $6,250

University of UtahNCT07521046

Observational

Revamping Exercise Assessments in Child Health (Project REACH)

This study is a cooperative investigation funded by the NIH. The project is a collaboration among three major NIH Clinical Translational Science Awardees: 1) U…

Cystic FibrosisSickle Cell DiseaseSARS CoV 2 Infection

Estimated

~$10 – $6,250

University of California, IrvineNCT05359991

Phase 3

A Double Blind, Randomized, Placebo-controlled Exploratory Trial to Investigate the Efficacy and Safety of Nerandomilast Over 24 Months When Administered in Individuals With Interstitial Lung Abnormalities and a Family History of Pulmonary Fibrosis to Reduce the Risk of Worsening (DROP-FPF)

This study is open to people aged 40 years or older who have at least 1 family member with pulmonary fibrosis. Pulmonary fibrosis is a condition where lung tis…

Familial Pulmonary FibrosisInterstitial Lung AbnormalitiesInterstitial Lung Diseases

Estimated

~$10 – $7,500

Boehringer IngelheimNCT07201922

Phase 2

A Phase 2a, Randomized, Open-Label, Active-Controlled, Crossover Study to Evaluate Safety and Explore Efficacy of Different Doses of New Lipase NHS7108 Administered Orally in Participants With Exocrine Pancreatic Insufficiency- EPIC

The purpose of this study is to measure the safety and explore the efficacy of 4 different doses of the new lipase NHS7108 in participants with EPI. In this st…

Exocrine Pancreatic Insufficiency (EPI)Cystic Fibrosis (CF)Pancreatic Enzyme Abnormality+1 more

Estimated

~$10 – $8,750

Aimmune Nestlé Health Science US R&D, LLCNCT07559175

Phase 2

Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis

The goal of this clinical trial is to gain more information about how fibroblast activation protein inhibitor (FAPI) binds to a certain type of cells in fibrot…

Fibrosis Lung

Estimated

~$10 – $6,250

University of Wisconsin, MadisonNCT06940427

Phase 3

A Phase 3, Randomized, Double-blind, Active-control Study of Pelabresib (DAK539) and Ruxolitinib vs. Placebo and Ruxolitinib in Adult Patients With Myelofibrosis Who Are JAK Inhibitor Naive

The purpose of this trial is to evaluate whether treatment with pelabresib in combination with ruxolitinib leads to improved clinical outcomes compared to ruxo…

Primary Myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis (PPV-MF)Post-essential Thrombocythemia Myelofibrosis (PET-MF)

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT07357727

Phase 1

A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients With Intermediate or High-Risk Primary or Secondary Myelofibrosis

This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (…

Myelofibrosis

Estimated

~$10 – $8,750

Sumitomo Pharma America, Inc.NCT04176198

Phase 2

A Randomized Phase 2 Trial of ASTX727 +/- Iadademstat in Accelerated/Blast-Phase Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs)

This phase II trial compares the effect of ASTX727 in combination with iadademstat to ASTX727 alone in treating patients with accelerated or blast phase Philad…

Accelerated Phase Myeloproliferative NeoplasmBlast Phase Myeloproliferative NeoplasmEssential Thrombocythemia+5 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06661915